| 1 | when | 73,105 |
| 2 | data.colloids | 3 |
| 3 | cfu/pt | 2 |
| 4 | danthron | 2 |
| 5 | 'clinimetrics | 1 |
| 6 | /quasi-rcts | 1 |
| 7 | 0.42±0.19 | 1 |
| 8 | 0.77±0.11 | 1 |
| 9 | 1.002-5.30 | 1 |
| 10 | 1.14-6.70 | 1 |
| 11 | 1.25-6.27 | 1 |
| 12 | 1.27-fold | 1 |
| 13 | 10.94±2.71 | 1 |
| 14 | 11.3g/dl | 1 |
| 15 | 16,943 | 1 |
| 16 | 165+/-129 | 1 |
| 17 | 3.44±0.87 | 1 |
| 18 | 5500-fold | 1 |
| 19 | 6.00-10.00 | 1 |
| 20 | 853+/-199 | 1 |
| 21 | a437g/k540e | 1 |
| 22 | a5199 | 1 |
| 23 | absorption/metabolism | 1 |
| 24 | acpoints | 1 |
| 25 | amodiaquine/kg | 1 |
| 26 | and-quinolones | 1 |
| 27 | based-uplc-esi-q-tof-ms/ms | 1 |
| 28 | c4-values | 1 |
| 29 | chemosensitizater | 1 |
| 30 | compressability | 1 |
| 31 | considered.- | 1 |
| 32 | energy-acceptor | 1 |
| 33 | ezelen | 1 |
| 34 | fc-receptor | 1 |
| 35 | fearfully | 1 |
| 36 | geometric-mean-ratios | 1 |
| 37 | lesislation | 1 |
| 38 | lmwsc | 1 |
| 39 | masseurs | 1 |
| 40 | mb445947 | 1 |
| 41 | model-tv-lag | 1 |
| 42 | ner-deficiency | 1 |
| 43 | nimotuzmab | 1 |
| 44 | non-orally | 1 |
| 45 | order-were | 1 |
| 46 | oxalmine | 1 |
| 47 | panavir | 1 |
| 48 | r-scripts | 1 |
| 49 | record3 | 1 |
| 50 | reults | 1 |
| 51 | tacr- | 1 |
| 52 | time-to-haemostasis | 1 |
| 53 | yfu | 1 |
| 54 | δagnb | 1 |
| 55 | €27 | 1 |
| 56 | ⋅4lb | 1 |
| 1 | 'clinimetrics | 1 |
| 2 | /quasi-rcts | 1 |
| 3 | 0.42±0.19 | 1 |
| 4 | 0.77±0.11 | 1 |
| 5 | 1.002-5.30 | 1 |
| 6 | 1.14-6.70 | 1 |
| 7 | 1.25-6.27 | 1 |
| 8 | 1.27-fold | 1 |
| 9 | 10.94±2.71 | 1 |
| 10 | 11.3g/dl | 1 |
| 11 | 16,943 | 1 |
| 12 | 165+/-129 | 1 |
| 13 | 3.44±0.87 | 1 |
| 14 | 5500-fold | 1 |
| 15 | 6.00-10.00 | 1 |
| 16 | 853+/-199 | 1 |
| 17 | a437g/k540e | 1 |
| 18 | a5199 | 1 |
| 19 | absorption/metabolism | 1 |
| 20 | acpoints | 1 |
| 21 | amodiaquine/kg | 1 |
| 22 | and-quinolones | 1 |
| 23 | based-uplc-esi-q-tof-ms/ms | 1 |
| 24 | c4-values | 1 |
| 25 | cfu/pt | 2 |
| 26 | chemosensitizater | 1 |
| 27 | compressability | 1 |
| 28 | considered.- | 1 |
| 29 | danthron | 2 |
| 30 | data.colloids | 3 |
| 31 | energy-acceptor | 1 |
| 32 | ezelen | 1 |
| 33 | fc-receptor | 1 |
| 34 | fearfully | 1 |
| 35 | geometric-mean-ratios | 1 |
| 36 | lesislation | 1 |
| 37 | lmwsc | 1 |
| 38 | masseurs | 1 |
| 39 | mb445947 | 1 |
| 40 | model-tv-lag | 1 |
| 41 | ner-deficiency | 1 |
| 42 | nimotuzmab | 1 |
| 43 | non-orally | 1 |
| 44 | order-were | 1 |
| 45 | oxalmine | 1 |
| 46 | panavir | 1 |
| 47 | r-scripts | 1 |
| 48 | record3 | 1 |
| 49 | reults | 1 |
| 50 | tacr- | 1 |
| 51 | time-to-haemostasis | 1 |
| 52 | when | 73,105 |
| 53 | yfu | 1 |
| 54 | δagnb | 1 |
| 55 | €27 | 1 |
| 56 | ⋅4lb | 1 |
| 1 | considered.- | 1 |
| 2 | tacr- | 1 |
| 3 | 6.00-10.00 | 1 |
| 4 | 1.002-5.30 | 1 |
| 5 | 1.14-6.70 | 1 |
| 6 | 0.77±0.11 | 1 |
| 7 | 10.94±2.71 | 1 |
| 8 | 16,943 | 1 |
| 9 | record3 | 1 |
| 10 | 1.25-6.27 | 1 |
| 11 | €27 | 1 |
| 12 | mb445947 | 1 |
| 13 | 3.44±0.87 | 1 |
| 14 | 0.42±0.19 | 1 |
| 15 | 165+/-129 | 1 |
| 16 | 853+/-199 | 1 |
| 17 | a5199 | 1 |
| 18 | nimotuzmab | 1 |
| 19 | ⋅4lb | 1 |
| 20 | δagnb | 1 |
| 21 | lmwsc | 1 |
| 22 | 5500-fold | 1 |
| 23 | 1.27-fold | 1 |
| 24 | a437g/k540e | 1 |
| 25 | oxalmine | 1 |
| 26 | order-were | 1 |
| 27 | model-tv-lag | 1 |
| 28 | amodiaquine/kg | 1 |
| 29 | 11.3g/dl | 1 |
| 30 | absorption/metabolism | 1 |
| 31 | when | 73,105 |
| 32 | ezelen | 1 |
| 33 | lesislation | 1 |
| 34 | danthron | 2 |
| 35 | chemosensitizater | 1 |
| 36 | panavir | 1 |
| 37 | energy-acceptor | 1 |
| 38 | fc-receptor | 1 |
| 39 | 'clinimetrics | 1 |
| 40 | data.colloids | 3 |
| 41 | and-quinolones | 1 |
| 42 | c4-values | 1 |
| 43 | time-to-haemostasis | 1 |
| 44 | based-uplc-esi-q-tof-ms/ms | 1 |
| 45 | geometric-mean-ratios | 1 |
| 46 | masseurs | 1 |
| 47 | /quasi-rcts | 1 |
| 48 | reults | 1 |
| 49 | acpoints | 1 |
| 50 | r-scripts | 1 |
| 51 | cfu/pt | 2 |
| 52 | yfu | 1 |
| 53 | ner-deficiency | 1 |
| 54 | non-orally | 1 |
| 55 | fearfully | 1 |
| 56 | compressability | 1 |